Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings Plc, a developer of novel immunotherapies for cancer, will present at the 8th Immuno-Oncology Summit Europe in London. CEO Professor Lindy Durrant will discuss the company’s melanoma vaccine SCIB1 and the Modi-1 vaccine, highlighting their recent positive clinical trial results and safety data. Scancell aims to revolutionize the treatment of cancer with its innovative vaccine technologies that have been gaining significant interest in the therapeutic cancer vaccine community.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
